Salud financiera de hoja de balance de TG Therapeutics
Salud financiera controles de criterios 5/6
TG Therapeutics tiene un patrimonio de accionistas total de $160.1M y una deuda total de $101.6M, lo que sitúa su ratio deuda-patrimonio en 63.5%. Sus activos y pasivos totales son $373.3M y $213.2M respectivamente. El BAIT de TG Therapeutics es de $48.4M, por lo que su ratio de cobertura de intereses es de 4. Tiene efectivo e inversiones a corto plazo que ascienden a $209.8M.
Información clave
63.5%
Ratio deuda-patrimonio
US$101.65m
Deuda
| Ratio de cobertura de intereses | 4x |
| Efectivo | US$209.79m |
| Patrimonio | US$160.11m |
| Total pasivo | US$213.21m |
| Activos totales | US$373.32m |
Actualizaciones recientes sobre salud financiera
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07Recent updates
Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($360.6M) de TGTX superan a sus pasivos a corto plazo ($99.7M).
Pasivo a largo plazo: Los activos a corto plazo de TGTX ($360.6M) superan a sus pasivos a largo plazo ($113.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: TGTX tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de TGTX ha pasado de 147.6% a 63.5% en los últimos 5 años.
Cobertura de la deuda: La deuda de TGTX no está bien cubierta por el flujo de caja operativo (20%).
Cobertura de intereses: Los pagos de intereses de la deuda de TGTX están bien cubiertos por el BAIT (4x cobertura).